WO2013028807A3 - Renal cell carcinoma biomarkers and uses thereof - Google Patents

Renal cell carcinoma biomarkers and uses thereof Download PDF

Info

Publication number
WO2013028807A3
WO2013028807A3 PCT/US2012/051944 US2012051944W WO2013028807A3 WO 2013028807 A3 WO2013028807 A3 WO 2013028807A3 US 2012051944 W US2012051944 W US 2012051944W WO 2013028807 A3 WO2013028807 A3 WO 2013028807A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell carcinoma
renal cell
biomarkers
rcc
carcinoma biomarkers
Prior art date
Application number
PCT/US2012/051944
Other languages
French (fr)
Other versions
WO2013028807A2 (en
Inventor
Rachel M. Ostroff
Stephen Alaric Williams
Michael Riel-Mehan
Edward N. Brody
Alex A.E. Stewart
Shintaro KATO
Original Assignee
Somalogic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic, Inc. filed Critical Somalogic, Inc.
Priority to EP12824991.9A priority Critical patent/EP2748356A2/en
Priority to MX2014002030A priority patent/MX2014002030A/en
Priority to CA2843756A priority patent/CA2843756A1/en
Publication of WO2013028807A2 publication Critical patent/WO2013028807A2/en
Publication of WO2013028807A3 publication Critical patent/WO2013028807A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/30—Microarray design
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/805—Haemoglobins; Myoglobins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Evolutionary Biology (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Biomarkers for the detecion of Renal Cell Carcinoma (RCC) in an individual are provided. More specifically, one or more biomarkers, methods, devices, reagents, systems, and kits for the evaluation of RCC are provided, wherein the evaluation may comprise diagnosis, prognosis, determination of disease burden or determination of recurrence of RCC in an individual.
PCT/US2012/051944 2011-08-22 2012-08-22 Renal cell carcinoma biomarkers and uses thereof WO2013028807A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP12824991.9A EP2748356A2 (en) 2011-08-22 2012-08-22 Renal cell carcinoma biomarkers and uses thereof
MX2014002030A MX2014002030A (en) 2011-08-22 2012-08-22 Renal cell carcinoma biomarkers and uses thereof.
CA2843756A CA2843756A1 (en) 2011-08-22 2012-08-22 Renal cell carcinoma biomarkers and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526133P 2011-08-22 2011-08-22
US61/526,133 2011-08-22

Publications (2)

Publication Number Publication Date
WO2013028807A2 WO2013028807A2 (en) 2013-02-28
WO2013028807A3 true WO2013028807A3 (en) 2014-05-15

Family

ID=47747076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/051944 WO2013028807A2 (en) 2011-08-22 2012-08-22 Renal cell carcinoma biomarkers and uses thereof

Country Status (5)

Country Link
US (2) US20130065782A1 (en)
EP (1) EP2748356A2 (en)
CA (1) CA2843756A1 (en)
MX (1) MX2014002030A (en)
WO (1) WO2013028807A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX341517B (en) 2010-08-13 2016-08-24 Somalogic Inc Pancreatic cancer biomarkers and uses thereof.
EP3825420A1 (en) * 2013-05-30 2021-05-26 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US9322051B2 (en) 2013-10-07 2016-04-26 General Electric Company Probing of biological samples
US10908156B2 (en) 2014-03-21 2021-02-02 Nephrogen, Inc. Portable instrument for in vitro detection and quantification of biomarkers
AU2018402956A1 (en) * 2018-01-16 2020-08-27 Public University Corporation Yokohama City University Renal cancer detection method and test drug
JP7339337B2 (en) 2018-11-07 2023-09-05 トラスティーズ オブ タフツ カレッジ Atomic force microscopy to identify surfaces
CN110361242B (en) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 Fixing liquid for eyeball tissue and pretreatment method for preparing eyeball tissue slices

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130193A1 (en) * 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2011050328A2 (en) * 2009-10-22 2011-04-28 The Regents Of The University Of California Assessment of solid tumor burden
US20110171633A1 (en) * 2010-01-11 2011-07-14 Wayne Cowens Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404926B2 (en) * 2010-01-29 2016-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130193A1 (en) * 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2011050328A2 (en) * 2009-10-22 2011-04-28 The Regents Of The University Of California Assessment of solid tumor burden
US20110171633A1 (en) * 2010-01-11 2011-07-14 Wayne Cowens Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Also Published As

Publication number Publication date
WO2013028807A2 (en) 2013-02-28
US20150160225A1 (en) 2015-06-11
CA2843756A1 (en) 2013-02-28
MX2014002030A (en) 2014-04-10
EP2748356A2 (en) 2014-07-02
US20130065782A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof
WO2012047618A3 (en) Mesothelioma biomarkers and uses thereof
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2014127290A3 (en) Methods for predicting risk of interstitial pneumonia
WO2012038463A3 (en) Use of myeloid cell biomarkers for the diagnosis of cancer
WO2011106709A3 (en) Epithelial biomarkers for cancer prognosis
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2012012725A3 (en) Methods of detecting diseases or conditions using phagocytic cells
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
MX340453B (en) Biomarkers for lung cancer.
AR066725A1 (en) PREDICTION OF THE FORECAST FOR MELANOMA DE CANCER
WO2012096545A3 (en) Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof
WO2013062515A3 (en) Lung cancer biomarkers and uses thereof
WO2012170206A3 (en) Color-producing diagnostic systems, reagents and methods
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2010009171A3 (en) Src activation for determining cancer prognosis and as a target for cancer therapy
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
WO2013044187A3 (en) Detecting ovarian cancer
WO2012061904A8 (en) Histone protein ubiquitination as a cancer biomarker
WO2014072832A3 (en) Biomarkers for cervical cancer
WO2014160237A3 (en) Methods of prognosing preeclampsia
WO2014052930A3 (en) Biomarkers for prostate cancer prognosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12824991

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2843756

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/002030

Country of ref document: MX